The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs

Molecular Pharmacology

Volumn 78, Issue 5, 2010, Pages 837-845

  Fortin, Jean Philippe ^a   Ci, Lei ^a   Schroeder, Jonathan ^a   Goldstein, Carmit ^a   Montefusco, Maria Claudia ^a   Peter, Inga ^b   Reis, Steven E ^c   Huggins, Gordon S ^a   Beinborn, Martin ^a   Kopin, Alan S ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CHLORNALTREXAMINE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENDOMORPHIN 1; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE ENKEPHALIN; LUCIFERASE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; NALOXONE; NALTREXONE;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ARTICLE; CELL STRAIN HEK293; CELL SURFACE; CONCENTRATION RESPONSE; DRUG POTENCY; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN VARIANT; REPORTER GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

AFRICAN AMERICANS; AMINO ACID SUBSTITUTION; CELL LINE; CHOLESTEROL, HDL; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, REPORTER; GENOTYPE; HUMANS; LUCIFERASES; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; PEPTIDES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; PROTEIN TRANSPORT; RADIOLIGAND ASSAY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 77958124076     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.064188     Document Type: Article

References (40)

1. Aiyer AN, Kip KE, Mulukutla SR, Marroquin OC, Hipps L Jr, and Reis SE (2007) Predictors of significant short-term increases in blood pressure in a community-based population. Am J Med 120:960-967.
2. Al-Fulaij MA, Ren Y, Beinborn M, and Kopin AS (2008) Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants. J Mol Neurosci 34:211-223.
3. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, and Kieffer BL (2001) A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276:3130-3137.
4. Beinborn M, Ren Y, Bläker M, Chen C, and Kopin AS (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65:753-760. (Pubitemid 38264043)
5. Bläker M, Ren Y, Gordon MC, Hsu JE, Beinborn M, and Kopin AS (1998) Mutations within the cholecystokinin-B/gastrin receptor ligand 'pocket' interconvert the functions of nonpeptide agonists and antagonists. Mol Pharmacol 54:857-863.
6. Bodnar RJ (2004) Endogenous opioids and feeding behavior: a 30-year historical perspective. Peptides 25:697-725.
7. Chen SL, Ma HI, Han JM, Tao PL, Law PY, and Loh HH (2007) dsAAV type 2-mediated gene transfer of MORS196A-EGFP into spinal cord as a pain management paradigm. Proc Natl Acad Sci USA 104:20096-20101.
8. Claude PA, Wotta DR, Zhang XH, Prather PL, McGinn TM, Erickson LJ, Loh HH, and Law PY (1996) Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc Natl Acad Sci USA 93:5715-5719.
9. Conklin BR, Farfel Z, Lustig KD, Julius D, and Bourne HR (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363:274-276. (Pubitemid 23158533)
10. Conn PM and Ulloa-Aguirre A (2010) Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs. Trends Endocrinol Metab 21:190-197.
11. Conn PM, Ulloa-Aguirre A, Ito J, and Janovick JA (2007) G protein-coupled receptor trafficking in health and disease: lessons learned to prepare for therapeutic mutant rescue in vivo. Pharmacol Rev 59:225-250. (Pubitemid 47481435)
12. Fortin JP, Schroeder JC, Zhu Y, Beinborn M, and Kopin AS (2010) Pharmacological characterization of human incretin receptor missense variants. J Pharmacol Exp Ther 332:274-280.
13. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590. (Pubitemid 27053295)
14. Greenway FL, Dunayevich E, Tollefson G, Erickson J, Guttadauria M, Fujioka K, Cowley MA, and NB-201 Study Group (2009) Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab 94:4898-4906.
15. Hearn MG, Ren Y, McBride EW, Reveillaud I, Beinborn M, and Kopin AS (2002) A Drosophila dopamine 2-like receptor: molecular characterization and identification of multiple alternatively spliced variants. Proc Natl Acad Sci USA 99:14554-14559. (Pubitemid 35257709)
16. Kazius J, Wurdinger K, van Iterson M, Kok J, Bäck T, and Ijzerman AP (2008) GPCR NaVa database: natural variants in human G protein-coupled receptors. Hum Mutat 29:39-44.
17. Kelley-Hedgepeth A, Peter I, Kip K, Montefusco M, Kogan S, Cox D, Ordovas J, Levy D, Reis S, Mendelsohn M, et al. (2008) The protective effect of KCNMB1 E65K against hypertension is restricted to blood pressure treatment with beta-blockade. J Hum Hypertens 22:512-515. (Pubitemid 351877740)
18. Koch T, Kroslak T, Averbeck M, Mayer P, Schröder H, Raulf E, and Höllt V (2000) Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol 58:328-334. (Pubitemid 30497476)
19. Kopin AS, McBride EW, Chen C, Freidinger RM, Chen D, Zhao CM, and Beinborn M (2003) Identification of a series of CCK-2 receptor nonpeptide agonists: sensitivity to stereochemistry and a receptor point mutation. Proc Natl Acad Sci USA 100:5525-5530. (Pubitemid 36542738)
20. Kroslak T, Laforge KS, Gianotti RJ, Ho A, Nielsen DA, and Kreek MJ (2007) The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103:77-87. (Pubitemid 47404205)
21. Laporte SA, Miller WE, Kim KM, and Caron MG (2002) Beta-Arrestin/AP-2 interaction in G protein-coupled receptor internalization: identification of a beta-arrestin binging site in beta 2-adaptin. J Biol Chem 277:9247-9254.
22. Le Merrer J, Becker JA, Befort K, and Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379-1412.
23. Leskelä TT, Markkanen PM, Pietilä EM, Tuusa JT, and Petäjä-Repo UE (2007) Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J Biol Chem 282:23171-23183.
24. Li J, Chen C, Huang P, and Liu-Chen LY (2001) Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 60:1064-1075. (Pubitemid 33027442)
25. Lötsch J and Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82-89. (Pubitemid 40193487)
26. Matthes HW, Smadja C, Valverde O, Vonesch JL, Foutz AS, Boudinot E, Denavit- Saubié M, Severini C, Negri L, Roques BP, et al. (1998) Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor. J Neurosci 18:7285-7295. (Pubitemid 28425813)
27. Moises HC, Rusin KI, and Macdonald RL (1994) mu-Opioid receptor-mediated reduction of neuronal calcium current occurs via a G(o)-type GTP-binding protein. J Neurosci 14:3842-3851.
28. North RA, Williams JT, Surprenant A, and Christie MJ (1987) Mu and delta receptors belong to a family of receptors that are coupled to potassium channels. Proc Natl Acad Sci USA 84:5487-5491. (Pubitemid 17129020)
29. Oertel BG, Kettner M, Scholich K, Renné C, Roskam B, Geisslinger G, Schmidt PH, and Lötsch J (2009) A common human μ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 284:6530-6535.
30. Przewłocki R and Przewłocka B (2001) Opioids in chronic pain. Eur J Pharmacol 429:79-91.
31. Rochdi MD, Vargas GA, Carpentier E, Oligny-Longpré G, Chen S, Kovoor A, Gitelman SE, Rosenthal SM, von Zastrow M, and Bouvier M (2010) Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments. Mol Pharmacol 77:836-845.
32. Roy S, Liu HC, and Loh HH (1998) mu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transit. Brain Res Mol Brain Res 56:281-283. (Pubitemid 28271686)
33. Samama P, Cotecchia S, Costa T, and Lefkowitz RJ (1993) A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268:4625-4636. (Pubitemid 23081571)
34. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416. (Pubitemid 35251788)
35. Sora I, Takahashi N, Funada M, Ujike H, Revay RS, Donovan DM, Miner LL, and Uhl GR (1997) Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci USA 94:1544-1549. (Pubitemid 27087888)
36. Strader CD, Candelore MR, Hill WS, Dixon RA, and Sigal IS (1989) A single amino acid substitution in the beta-adrenergic receptor promotes partial agonist activity from antagonists. J Biol Chem 264:16470-16477.
37. Tabarin A, Diz-Chaves Y, Chaves YD, Carmona Mdel C, Catargi B, Zorrilla EP, Roberts AJ, Coscina DV, Rousset S, Redonnet A, et al. (2005) Resistance to diet-induced obesity in mu-opioid receptor-deficient mice: evidence for a "thrifty gene". Diabetes 54:3510-3516.
38. Wang D, Quillan JM, Winans K, Lucas JL, and Sadée W (2001) Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 276:34624-34630.
39. Zheng H, Loh HH, and Law PY (2008) Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation. Mol Pharmacol 73:178-190. (Pubitemid 350294209)
40. Zuberi AR, Townsend L, Patterson L, Zheng H, and Berthoud HR (2008) Increased adiposity on normal diet, but decreased susceptibility to diet-induced obesity in mu-opioid receptor-deficient mice. Eur J Pharmacol 585:14-23.